Top 10 stocks. Once a month. Expert picks, straight to your inbox.See the newsletter
GeneDx logo

GeneDx

WGS
$67.86
+21%since Benson's first pick

Market price data through August 3, 2026.

Performance

Aug 2021Aug 2026

Benson's first pick
$0$145$291$436Aug 2021Oct 2022Feb 2024May 2025Aug 2026Benson picked · $84.02
Model signal
Sell
What Benson's model currently says about this stock.
Benson rating
3.5 / 5
Benson's overall conviction in this stock right now.
Risk
High risk
How bumpy the ride tends to be with this stock.

Track record

How this pick has done since Benson first called it.

Benson Return
+21%
How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
First pick price
~$56
Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
Tracking since
October 2024
The month this stock first became a Benson pick.
Tracking duration
21 months
How long Benson has been tracking this pick.

About GeneDx

GeneDx is like a detective agency for DNA. Doctors send them blood samples from kids with mysterious illnesses, and GeneDx reads the genetic code to figure out what's wrong, using the world's largest library of rare disease DNA.

The case for and against

Both sides of the story, in plain English.

Bull case
  • Volume Surge

    GeneDx ran 27,488 advanced DNA tests last quarter, up 34 percent from a year ago. That's like a pizza shop going from selling 100 pizzas a day to 134 pizzas a day, and every test makes their giant DNA library smarter for the next kid who needs answers.

  • Doctor Endorsed

    A major study just showed GeneDx testing saves up to 80,000 dollars per child in healthcare costs over the year after the test. Plus three more states added Medicaid coverage, giving 4.9 million more low-income kids access. When testing saves money AND saves lives, hospitals keep ordering more.

Bear case
  • Guidance Cut

    GeneDx just slashed its full-year revenue forecast from 540 million dollars down to 475 million, and flipped from expecting profits to expecting an 8 million dollar loss this quarter. Volume keeps growing fast but the dollars per test are slipping, which spooked the market hard.

  • Pricing Pressure

    Insurance companies still reject a huge chunk of GeneDx's bills, and as the company pushes into new markets like general pediatricians, payment rates get even messier before they get better. With a stock beta of 2.07, this thing swings twice as wildly as the overall market on any bad news.

How to read this page

This automated research summary uses Financial Modeling Prep market data through 2026-08-03. Model signals, scores, and risk labels can change and may be incomplete or wrong.

Want Benson to watch WGS for you?

Get the app to follow every Benson pick live — and let Benson do the research for you.